Drugs in MeSH Category Coccidiostats

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Everylife	SULFADIAZINE	sulfadiazine	TABLET;ORAL	080088-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Lederle	SULFADIAZINE	sulfadiazine	TABLET;ORAL	004054-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Lilly	SULFADIAZINE	sulfadiazine	TABLET;ORAL	004122-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Chartwell Molecular	SULFADIAZINE	sulfadiazine	TABLET;ORAL	080084-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Epic Pharma Llc	SULFADIAZINE	sulfadiazine	TABLET;ORAL	040091-001	Jul 29, 1994		RX	No	Yes

Coccidiostats Market Analysis and Financial Projection

The coccidiostat market is experiencing significant growth driven by rising global protein demand and intensive livestock farming, while facing challenges from drug resistance and regulatory pressures. Below is a structured analysis of market dynamics and patent trends for these antiparasitic agents:

Market Dynamics

Growth Projections

• Valued at $1.2–1.5 billion in 2023, the market is projected to reach $2.1–2.5 billion by 2033, growing at a 6–8% CAGR[1][7].
• Key drivers include:
  • Increasing meat consumption (projected to rise by 1.4% annually, reaching 400 million tons by 2025[1][11]).
  • Economic impact of coccidiosis, which reduces livestock productivity by up to 20%[11].
  • Expanding poultry production (~9 billion broiler chickens annually in the U.S. alone[1][7]).

Regional Trends

• North America and Europe dominate due to advanced farming practices and strict regulations[7].
• Asia-Pacific is the fastest-growing region, fueled by rising poultry consumption in China and India[7][16].

Key Players

• Major companies include Elanco, Zoetis, and Huvepharma, focusing on ionophores (monensin, salinomycin) and synthetic compounds (diclazuril)[4][7].
• Feed anticoccidials represent a $429 million submarket, growing at 4.4% CAGR[4].

Patent Landscape

Innovation Trends

• Formulation advancements: Patents like CN101129390A (compound coccidiostat solutions[5]) and JP2001354580A (natural extracts from oregano/clove[18]) address solubility and resistance issues.
• Regional dominance:
  • U.S. leads with ~90 patent families, followed by Australia and Japan[2].
  • EU and China focus on niche innovations, including repurposed drugs for rare diseases[9][12].

Expiring Patents

• Tudorza Pressair (COPD drug repurposed for poultry) and Duaklir Pressair expire in February 2025, opening opportunities for generics[10].
• 65+ drug patents expire in 2025, including Sprycel (leukemia) and Kyprolis (myeloma)[13][16].

---

Challenges & Regulatory Shifts

Factor	Impact
Drug resistance	~80% of Eimeria strains show resistance to common coccidiostats[6][11]
Residue concerns	EFSA reports low but persistent residues in poultry products[11]
Regulatory tightening	EU mandates veterinary prescriptions for coccidiostats by 2025[11]
Shift to alternatives	Vaccines and probiotics capturing 15–20% market share[1][7]

Emerging Solutions

• Natural additives: Phytogenic blends (e.g., nutmeg, rosemary) gaining traction[18].
• Precision delivery: Nanoparticle-based formulations improving bioavailability[5].

---

Strategic Implications

• Generics market: Patent expirations will reduce prices by 30–40%, benefiting developing economies[10][13].
• Sustainability focus:
  • Probiotic-based solutions growing at 12% CAGR[7].
  • Vaccine adoption rising in Europe due to antibiotic-reduction policies[11].

The coccidiostat sector remains critical for global food security, balancing innovation with evolving regulatory and environmental demands. Companies investing in dual-action formulations and residue-free alternatives are likely to lead the next growth phase.

References

1. https://www.verifiedmarketreports.com/product/coccidiostat-market/
2. https://ipmall.info/sites/default/files/hosted_resources/PatentLandscape/Malaria%20Final%20Draft%20v2.pdf
3. https://decs.bvsalud.org/en/ths/?filter=ths_termall&q=Coccidiostats
4. https://www.marketsandmarkets.com/PressReleases/feed-anticoccidial.asp
5. https://patents.google.com/patent/CN101129390A/en
6. https://pubmed.ncbi.nlm.nih.gov/24534603/
7. https://datahorizzonresearch.com/coccidiostat-market-4931
8. https://patents.google.com/patent/US3830928A/en
9. https://drugrepocentral.scienceopen.com/hosted-document?doi=10.58647%2FDRUGREPO.24.1.0012
10. https://www.pharmamanufacturing.com/home/article/55249347/key-drugs-losing-patent-protection-in-2025
11. https://pmc.ncbi.nlm.nih.gov/articles/PMC9497773/
12. https://drugrepocentral.scienceopen.com/hosted-document?doi=10.58647%2FDRUGARXIV.PR000009.v1
13. https://www.greyb.com/blog/drug-patents-expiring-2025/
14. http://www.pjmonline.org/wp-content/uploads/fullissues/vol7022021.pdf
15. https://inventionip.com/patent-landscape-analysis/
16. https://biopharmaapac.com/analysis/60/5727/25-high-value-drugs-losing-patent-protection-in-2025-what-it-means-for-healthcare.html
17. https://patents.google.com/patent/CN101559074A/en
18. https://patents.google.com/patent/JP2001354580A/en
19. https://www.marketresearchintellect.com/product/global-coccidiostat-consumption-market-size-and-forecast/